Presenting Coramed Technologies

Coramed Technologies was launched in 2008 by the founders of Haemoscope Corporation, creators of the currently marketed TEG® 5000 hemostasis analyzer. While the TEG 5000 is a successful, industry-leading instrument, it can only be used in a laboratory or hospital setting. Coramed is developing new CORA™ technology that will lead to a smaller, easier-to-use, CLIA-waived device that can be operated virtually anywhere.

Eli Cohen, Ph.D., Co-founder and CEO

Dr. Cohen brings more than 30 years of experience leading medical instrument and software firms, as well as a decade as an educator, to his work at Coramed. He began his career teaching courses in statistics and research methodology at Northwestern University, before co-founding his own database management company in 1980. After 11 years in software, Dr. Cohen a co-founded Haemoscope Corporation, makers of the TEG family of coagulation measurement instruments. By November 2007, Haemoscope sold its TEG technology, including patents and trademarks and its manufacturing and distribution arm to Haemonetics Corporation (symbol “HAE”) and renamed itself Coramed Technologies, LLC.

Dr. Cohen has published extensively on the value of thrombelastography and complete hemostasis measurement, and has served as principal investigator in related phase I and II research. He is a member of the American Statistical Association and Gamma Sigma Delta Honor Society.

Dr. Cohen earned his Bachelor of Science degree in genetics at The Hebrew University in Jerusalem, and his master’s and Ph.D. at the University of Manitoba. He performed post-doctoral work in quantitative genetics at the University of Nebraska, then earned a Master of Science degree in statistics from Iowa State University.

Gabriel Raviv, Ph.D., Co-founder and President

Dr. Raviv has over 30 years of development and business experience in the medical device industry. He co-founded Bio-logic Systems Corp., an audiological and neurological device company which was taken public in 1983. Dr. Raviv was Bio-logic’s chairman and CEO from its inception until it was sold to Natus, Inc. (symbol “BABY”) in January, 2006. Dr. Raviv was also a co-founder of Haemoscope Corporation, makers of the TEG family of coagulation measurement instruments. Following the sale of Bio-logic, Dr. Raviv joined Haemoscope as president. By November 2007, Haemoscope sold its TEG technology, including patents and trademarks and its manufacturing and distribution arm to Haemonetics Corporation (symbol “HAE”) and renamed itself Coramed Technologies, LLC.

Dr. Raviv has served on the board of trustees of the Midwest Bio-Laser institute and was the winner of the High Tech Entrepreneur of the Year Award in 1986. He was a member of the advisory board at Purdue-Indiana University Medical Center Joint Au.D. Program and the Executive Council for the Division of Sleep Medicine at Harvard University School. He has authored and co-authored several scientific articles has authored more than a dozen patents and has been a principal investigator on several phase I and II NIH SBIR grants. Dr. Raviv serves on several boards of medical companies, none of which poses a conflict with his duties at Coramed Technologies.

Dr. Raviv earned his Bachelor of Science degree in physics and mathematics from The Hebrew University in Jerusalem and in electrical engineering from the Technion (Israel Institute of Technology). He continued his education at Northwestern University where he earned his master’s and Ph.D. in biomedical and electrical engineering.

Peter Delmenico, Director of Engineering

Throughout his 20-year career with IDEO Product Development, his own engineering research firm, Haemoscope Corporation and now Coramed, Peter has been integral to the development of the original TEG system and consumables, as well as next-generation CORA technology.

In addition to his work in coagulation monitoring, Peter has developed products for high-volume consumer products, office products, power tools, and a number of other medical instruments. As a result, he has extensive experience in diagnostic and therapeutic systems, electromechancial systems, rapid prototyping, and production machining.

Peter earned his bachelor’s and master’s degrees in mechanical engineering from Washington University. He has authored more than a dozen patents.

Norm Brunner, Director of RA/QA

As head of regulatory affairs and quality assurance, Norm Brunner works closely with the engineering team, vendors, and the FDA to ensure that the CORA system meets FDA requirements. Throughout most of his 35-year career, Norm has been an adjunct professor of electronics and software at the College of Lake County. He has also worked with and led engineering teams at Abbott Laboratories, Powers Regulator Company, Teletype Corporation (now part of AT&T) and Bally Manufacturing. He has also provided regulatory and quality guidance for the TEG system, as well as products by Bio-logic Systems.

He is a member of the American Society for Quality, Association for the Advancement of Medical Instrumentation, Institute of Electrical and Electronics Engineers, and Regulatory Affairs Professional Society.

Norm earned his bachelor’s and master’s degrees in electrical engineering from Northwestern University before earning his MBA from the Lake Forest Graduate School of Management. He was awarded the NFS Fellowship for one-year residency and Ovid W. Eshbach Honor as the top technological institute student at Northwestern.

Carlos G. Lopez-Espina, Sr Engineer

Originally focused on new technologies at Haemoscope Corporation, Carlos joined the Coramed team to develop the core measurement technology and microfluidics disposables used in the CORA system.

Carlos earned his M.S. from the University of Illinois at Chicago.

Coramed Technologies Patents

  • Method and Apparatus for Monitoring Anti-Platelet Agents 6,613,573
  • Protocol for Monitoring Platelet Inhibition 7,179,652
  • Protocol for Monitoring Platelet Inhibition 7,732,213
  • Protocol for Monitoring Direct Thrombin Inhibition (Pending)
  • Protocol for Stratification of Ischemic Risk and Optimized Individualized Treatment 7,754,489
  • Protocol for Stratification of Ischemic Risk and Optimized Individualized Treatment (Pending)
  • Method and Apparatus for Monitoring Haemostasis 6,797,519
  • Method and Apparatus for Haemostasis and Blood management 6,787,363
  • Protocol and Apparatus for Determining Heparin-Induced Thrombocytopenia 7,524,670
  • Protocol and Apparatus for Determining Heparin-Induced Thrombocytopenia 7,811,792
  • Method and Apparatus for Measuring Hemostasis 7,261,861
  • Method and Apparatus for Measuring Hemostasis 7,879,615
  • Apparatus and Cartridge for Hemostasis Testing 9,068,966
  • Other patents pending

TEG is a registered trademark of Haemonetics Corporation

About Us

Coramed is mapping the future of personalized hemostasis therapy.